JAK/STAT5 signaling pathway inhibitor ruxolitinib reduces airway inflammation of neutrophilic asthma in mice model.

Ruxolitinib may suppress the survival of Th17 cells by inhibiting the JAK/STAT5 signaling pathway and regulate the anti-apoptosis proteins Bcl-2 and Caspase3, thus promoting the increase of Thl7 cells entering the apoptotic pathway and reducing airway inflammation in NA mice.